Renal cancer response to rapamycin analog CCI-779 treatment: time course
Summary:
Expression profiling of peripheral blood mononuclear cells (PBMC) from patients with advanced renal cancer following treatment with the rapamycin analog CCI-779. Gene expression examined 8 and 16 weeks after treatment. Results identify potential gene markers of CCI-779 exposure.
GPL8300:
[HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array
Citation:
Boni JP, Leister C, Bender G, Fitzpatrick V et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005 Jan;77(1):76-89. PMID: 15637533
